{"id":3064,"date":"2016-06-15T06:30:00","date_gmt":"2016-06-15T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/first-patient-in-primecc-study-included\/"},"modified":"2016-06-15T06:30:00","modified_gmt":"2016-06-15T06:30:00","slug":"first-patient-in-primecc-study-included","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/","title":{"rendered":"First patient in PrimECC study included"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>PrimECC<sup>\u00ae<\/sup> is a CE-marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery. A previous \u201cproof of concept\u201d study performed using PrimECC<sup>\u00ae<\/sup> has shown interesting clinical results. The study that has now been started is intended to expand the clinical documentation for PrimECC<sup>\u00ae<\/sup> and will include a total of 80 patients.<\/strong><\/div>\n<p><span>Several hundred thousand heart operations are performed in the world each year using a heart-lung machine and the \u2018proof of concept\u2019 study performed using PrimECC<sup>\u00ae<\/sup> indicates\u00a0 that the patient has an improved fluid balance after the operation if the heart-lung machine is primed with PrimECC<sup>\u00ae<\/sup> rather than the simpler solutions that are often used. In order to expand the documentation the company will perform a randomized clinical study on 80 patients at Sahlgrenska University Hospital in Gothenburg in 2016. XVIVO does not plan any extensive launch of the product before this study is complete. XVIVO Perfusion has applied for a patent for PrimECC<sup>\u00ae<\/sup> in important markets and has so far been granted a patent in the USA and EU.<\/span><\/p>\n<p><span>PrimECC<\/span><strong><span><sup>\u00ae<\/sup><\/span><\/strong><span> is a fluid developed in collaboration with Professor Stig Steen in Lund to prime heart-lung machines before use. These machines are used to maintain blood circulation and take over oxygenation of the blood during heart operations. The fluid is used to compensate for the volume of blood that is outside the patient and in the heart-lung machine during the operation. Today simple saline solutions are used which are not optimized for this purpose. The aim of PrimECC<sup>\u00ae<\/sup> is to minimize adverse effects that may arise during and after use of a heart-lung machine. <\/span><\/p>\n<p><span>\u201cWe are delighted that the clinical study using PrimECC has now started as the product has interesting clinical and commercial potential,\u201d says XVIVO Perfusion\u2019s CEO Magnus Nilsson. <\/span><\/p>\n<p><span>June 15, 2016<br \/><\/span>Gothenburg<br \/>XVIVO Perfusion AB (publ)<\/p>\n<div class=\"mfn-footer\">\n<p><span>For further information please contact:<\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span><br \/><span>For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n<p><span>The information was submitted for publication on\u00a0June15, 2016\u00a0at 8:30 a.m.<\/span><\/p>\n<p><span>This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PrimECC\u00ae is a CE-marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery. A previous \u201cproof&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3064","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First patient in PrimECC study included - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First patient in PrimECC study included - XVIVO\" \/>\n<meta property=\"og:description\" content=\"PrimECC\u00ae is a CE-marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery. A previous \u201cproof...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-patient-in-primecc-study-included\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-patient-in-primecc-study-included\\\/\",\"name\":\"First patient in PrimECC study included - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-06-15T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-patient-in-primecc-study-included\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-patient-in-primecc-study-included\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/first-patient-in-primecc-study-included\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First patient in PrimECC study included\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First patient in PrimECC study included - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/","og_locale":"en_US","og_type":"article","og_title":"First patient in PrimECC study included - XVIVO","og_description":"PrimECC\u00ae is a CE-marked and patent-protected product, developed to prime the heart-lung machine before open heart surgery. A previous \u201cproof...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/","name":"First patient in PrimECC study included - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-06-15T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/first-patient-in-primecc-study-included\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"First patient in PrimECC study included"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}